Comparison of Diuretic Effects between Empagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor With Osmotic Diuresis, and Tolvaptan, a Water Diuretic, in Two Type 2 Diabetic Patients Taking Sodium Diuretics

Authors

  • Yuji Aoki Department of Internal Medicine, National Hospital Organization, Matsumoto Medical Center, Matsumoto Hospital, Murai, Matsumoto 399-8701, Japan

DOI:

https://doi.org/10.17140/DROJ-2-128

Keywords:

Sodium-glucose co-transporter 2 inhibitor (SGLT2 inhibitor), Empagliflozin Osmotic diuresis, Tolvaptan Water diuresis, Sodium diuresis

Abstract

Empagliflozin, one of sodium-glucose co-transporter 2 (SGLT2) inhibitors, has been demonstrated to have beneficial effects on cardiovascular morbidity and mortality in patients with type 2 diabetes at high risk for cardiovascular events. The mechanisms behind these benefits of empagliflozin are presumed to include osmotic diuresis, being rather close to water diuresis than sodium diuresis. Two cases are presented here, where distinct changes in urinary water and sodium excretion were seen immediately after replacing tolvaptan, a water diuretic, with empagliflozin. Case 1 with heart failure showed a large decrease in urinary sodium excretion with a slight decrease in urine volume. By contrast, Case 2 with nephrotic syndrome showed a large increase in urinary sodium excretion with an increase in urine volume. The differences were probably due to distinct diuretic effects of empagliflozin and tolvaptan in the presence of sodium diuretics as well as distinct pathological conditions. In addition, the amount of urine protein was reduced after the replacement in Case 2. SGLT2 inhibitors would be expected to have the potential to exert some beneficial effects other than lowering blood glucose levels by increasing urinary glucose excretion.

References

Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, car-diovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373: 2117-2128. doi: 10.1056/NEJMoa1504720

Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016; 375: 323-334. doi: 10.1056/NEJMoa1515920

Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high car-diovascular risk: Results of the EMPA-REG OUTCOME trial. Eur Heart J. 2016; 37(19): 1526-1534. doi: 10.1093/eurheartj/ ehv728

Bernstein LM, Blumberg B, Arkin MC. Osmotic diuretic treat-ment of refractory edema. Circulation. 1958; 17: 1013-1020. doi: 10.1161/01.CIR.17.6.1013

Aoki Y. Administration of sodium-glucose co-transporter 2 inhibitors could accelerate dehydration in poorly-controlled dia-betic patients, proposing an option not to increase glucosuria but to decrease carbohydrate intake during hyperglycemia. Diabetes Res Open J. 2015;1: 72-74. doi: 10.17140/DROJ-1-111

Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selec-tive oral vasopressin V -receptor antagonist, for hyponatremia. N Engl J Med. 2006; 355: 2099-2112.

Aoki Y. Surprising results of the EMPA-REG OUTCOME study have brought a new insight into use of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes. Trop Med Surg. 2015; 3: 199. doi: 10.4172/2329-9088.1000199

Katsuno K, Fujimori Y, Takemura Y, et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose reab-sorption and modulates plasma glucose level. J Pharmacol Exp Ther. 2007; 320: 323-330. doi: 10.1124/jpet.106.110296

Lin B, Koibuchi N, Hasegawa Y, et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014; 13: 148. doi:

1186/s12933-014-0148-1 10. Kasichayanula S, Liu X, Pe Benito M, et al. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol. 2013; 76: 432-444. doi: 10.1111/bcp.12056

Sarashina A, Ueki K, Sasaki T, et al. Effect of renal impair-ment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus. Clin Ther. 2014; 36: 1606-1615. doi: 10.1016/j.clinthera.2014.08.001

List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabe-tes. Diabetes Care. 2009; 32: 650-657. doi: 10.2337/dc08-1863

Devineni D, Curtin CR, Polidori D, et al. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol. 2013; 53: 601-610. doi: 10.1002/jcph.88

Kanada S, Koiwai K, Taniguchi A, Sarashina A, Seman L, Woerle HJ. Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks’ treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus. J Diabetes Invest. 2013; 4: 613-617. doi: 10.1111/jdi.12110

Scholl-Buergi S, Santer R, Ehrich JHH. Long-term outcome of renal glucosuria type 0: the original patient and his natural history. Nephrol Dial Transplant. 2004; 19: 2394-2396. doi: 10.1093/ndt/gfh366

Calado J, Sznajer Y, Metzger D, et al. Twenty-one additional cases of familial renal glucosuria: absence of genetic heteroge-neity, high prevalence of private mutations and further evidence of volume depletion. Nephrol Dial Transplant. 2008; 23: 3874- 3879. doi: 10.1093/ndt/gfn386

Matsuzaki M, Hori M, Izumi T, Fukunami M. Efficacy and safety of tolvaptan in heart failure patients with volume over-load despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther. 2011; 1: S33-S45. doi: 10.1007/s10557-011-6304-x

Patra S, Kumar B, Harlalka KK, et al. Short term efficacy and safety of low dose tolvaptan in patients with acute decom-pensated heart failure with hyponatremia: A prospective obser-vational pilot study from a single center in South India. Heart Views. 2014; 15: 1-5. doi: 10.4103/1995-705X.132136

Chao EC, Henry RR. SGLT2 inhibition – anovel strategy for diabetes treatment. Nat Rev Drug Discov. 2010; 9: 551-559. doi: 10.1038/nrd3180

Cherney DZI, Perkins BA, Soleymanlou N, et al. Renal he-modynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014; 129: 587-597. doi: 10.1161/CIRCULATIONAHA.113.005081

Shawkat H, Westwood M-M, Mortimer A. Mannitol: A re-view of its clinical uses. Contin Educ Anaesth Crit Care Pain. 2012; 1-4. doi: 10.1093/bjaceaccp/mkr063

Heerspink HJL, Desai M, Jardine M, Balis D, Meininger G, Perkovic V. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol. 2016; 28. doi: 10.1681/ASN.2016030278

Downloads

Published

2016-10-28

How to Cite

Yuji Aoki. (2016). Comparison of Diuretic Effects between Empagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor With Osmotic Diuresis, and Tolvaptan, a Water Diuretic, in Two Type 2 Diabetic Patients Taking Sodium Diuretics. Diabetes Research, 2(2), 45–49. https://doi.org/10.17140/DROJ-2-128

Issue

Vol. 2 No. 2 (2016): Volume 2 Issue 2 2016

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content published in Diabetes Research (DR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.